Baidu
map

2020 SIR临床实践指南:风湿性多肌痛的管理

2020-04-10 意大利风湿病学学会 Reumatismo. 2020 Apr 10;72(1):1-15.

2020年4月,意大利风湿病学学会(SIR)发布了风湿性多肌痛的管理指南,主要目的是针对风湿性多肌痛患者的临床管理提供最新的循证指导建议,内容涉及风湿性多肌痛的临床评估,实验室检查,特殊检查,一线治疗

中文标题:

2020 SIR临床实践指南:风湿性多肌痛的管理

英文标题:

The Italian Society of Rheumatology clinical practice guidelines for the management of polymyalgia rheumatica.

发布机构:

意大利风湿病学学会

发布日期:

2020-04-10

简要介绍:

2020年4月,意大利风湿病学学会(SIR)发布了风湿性多肌痛的管理指南,主要目的是针对风湿性多肌痛患者的临床管理提供最新的循证指导建议,内容涉及风湿性多肌痛的临床评估,实验室检查,特殊检查,一线治疗,二线治疗,非药物干预,治疗目标和随访。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 SIR临床实践指南:风湿性多肌痛的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=8abe91c0018969d2, title=2020 SIR临床实践指南:风湿性多肌痛的管理, enTitle=The Italian Society of Rheumatology clinical practice guidelines for the management of polymyalgia rheumatica., guiderFrom=Reumatismo. 2020 Apr 10;72(1):1-15., authorId=0, author=, summary=2020年4月,意大利风湿病学学会(SIR)发布了风湿性多肌痛的管理指南,主要目的是针对风湿性多肌痛患者的临床管理提供最新的循证指导建议,内容涉及风湿性多肌痛的临床评估,实验室检查,特殊检查,一线治疗, cover=https://img.medsci.cn/2020427/1587994386316_2020535.jpg, journalId=0, articlesId=null, associationId=1454, associationName=意大利风湿病学学会, associationIntro=, copyright=0, guiderPublishedTime=Fri Apr 10 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年4月,意大利风湿病学学会(SIR)发布了风湿性多肌痛的管理指南,主要目的是针对风湿性多肌痛患者的临床管理提供最新的循证指导建议,内容涉及风湿性多肌痛的临床评估,实验室检查,特殊检查,一线治疗,二线治疗,非药物干预,治疗目标和随访。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=20209, tagName=风湿性多肌痛)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=20209, guiderKeyword=风湿性多肌痛, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2394, appHits=244, showAppHits=17, pcHits=699, showPcHits=2168, likes=1, shares=19, comments=9, approvalStatus=1, publishedTime=Tue Apr 28 12:59:37 CST 2020, publishedTimeString=2020-04-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Apr 27 21:33:43 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 14:22:35 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 SIR临床实践指南:风湿性多肌痛的管理.pdf)])
2020 SIR临床实践指南:风湿性多肌痛的管理.pdf
下载请点击:
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1074476, encodeId=df3b10e44769c, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64d15223317, createdName=14784d57m94暂无昵称, createdTime=Sat Nov 27 12:36:28 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062279, encodeId=342e10622e9fa, content=11, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f82513133, createdName=124c32bfm02暂无昵称, createdTime=Wed Oct 20 15:26:29 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999006, encodeId=1dd999900662, content=222, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=59087105, createdTime=Tue Jul 13 08:39:09 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999004, encodeId=3de09990049a, content=啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=ms6000000959087105, createdTime=Tue Jul 13 08:27:35 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999003, encodeId=4a7d999003ac, content=啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=ms6000000959087105, createdTime=Tue Jul 13 08:27:01 CST 2021, time=2021-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1074476, encodeId=df3b10e44769c, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64d15223317, createdName=14784d57m94暂无昵称, createdTime=Sat Nov 27 12:36:28 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062279, encodeId=342e10622e9fa, content=11, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f82513133, createdName=124c32bfm02暂无昵称, createdTime=Wed Oct 20 15:26:29 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999006, encodeId=1dd999900662, content=222, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=59087105, createdTime=Tue Jul 13 08:39:09 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999004, encodeId=3de09990049a, content=啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=ms6000000959087105, createdTime=Tue Jul 13 08:27:35 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999003, encodeId=4a7d999003ac, content=啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=ms6000000959087105, createdTime=Tue Jul 13 08:27:01 CST 2021, time=2021-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1074476, encodeId=df3b10e44769c, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64d15223317, createdName=14784d57m94暂无昵称, createdTime=Sat Nov 27 12:36:28 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062279, encodeId=342e10622e9fa, content=11, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f82513133, createdName=124c32bfm02暂无昵称, createdTime=Wed Oct 20 15:26:29 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999006, encodeId=1dd999900662, content=222, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=59087105, createdTime=Tue Jul 13 08:39:09 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999004, encodeId=3de09990049a, content=啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=ms6000000959087105, createdTime=Tue Jul 13 08:27:35 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999003, encodeId=4a7d999003ac, content=啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=ms6000000959087105, createdTime=Tue Jul 13 08:27:01 CST 2021, time=2021-07-13, status=1, ipAttribution=)]
    2021-07-13 59087105

    222

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1074476, encodeId=df3b10e44769c, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64d15223317, createdName=14784d57m94暂无昵称, createdTime=Sat Nov 27 12:36:28 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062279, encodeId=342e10622e9fa, content=11, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f82513133, createdName=124c32bfm02暂无昵称, createdTime=Wed Oct 20 15:26:29 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999006, encodeId=1dd999900662, content=222, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=59087105, createdTime=Tue Jul 13 08:39:09 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999004, encodeId=3de09990049a, content=啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=ms6000000959087105, createdTime=Tue Jul 13 08:27:35 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999003, encodeId=4a7d999003ac, content=啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=ms6000000959087105, createdTime=Tue Jul 13 08:27:01 CST 2021, time=2021-07-13, status=1, ipAttribution=)]
    2021-07-13 ms6000000959087105

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1074476, encodeId=df3b10e44769c, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64d15223317, createdName=14784d57m94暂无昵称, createdTime=Sat Nov 27 12:36:28 CST 2021, time=2021-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062279, encodeId=342e10622e9fa, content=11, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4f82513133, createdName=124c32bfm02暂无昵称, createdTime=Wed Oct 20 15:26:29 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999006, encodeId=1dd999900662, content=222, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=59087105, createdTime=Tue Jul 13 08:39:09 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999004, encodeId=3de09990049a, content=啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=ms6000000959087105, createdTime=Tue Jul 13 08:27:35 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999003, encodeId=4a7d999003ac, content=啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210713/6e97a11b82da4a93ab3d122d922a2c7c/f97dc13c6ba649a98b0df4d42b35a55b.jpg, createdBy=39ee5547494, createdName=ms6000000959087105, createdTime=Tue Jul 13 08:27:01 CST 2021, time=2021-07-13, status=1, ipAttribution=)]
    2021-07-13 ms6000000959087105

    0

拓展阅读

2023 巨细胞动脉炎和风湿性多肌痛的靶向治疗建议

国外风湿免疫科相关专家小组 · 2023-02-24

2024 SFR建议:风湿性多肌痛患者的当前实践管理

法国风湿病学学会(SFR,French Society for Rheumatology) · 2024-04-05

Baidu
map
Baidu
map
Baidu
map